Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder

This study has been completed.
Information provided by (Responsible Party):
Shire Identifier:
First received: March 6, 2012
Last updated: June 6, 2014
Last verified: June 2014

The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).

Condition Intervention Phase
Attention-deficit/Hyperactivity Disorder
Drug: Lisdexamfetamine dimesylate
Drug: Methylphenidate Hydrochloride
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared With OROS-MPH (CONCERTA®) With a Placebo Reference Arm, in Adolescents Aged 13-17 Years With Attention-deficit/Hyperactivity Disorder (ADHD)

Resource links provided by NLM:

Further study details as provided by Shire:

Primary Outcome Measures:
  • Change from Baseline in Attention-Deficit/Hyperactivity Disorder Rating Scale, Fourth Edition (ADHD-RS-IV) Total Score at up to 6 Weeks [ Time Frame: Baseline and up to 6 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Percent of Participants With Improvement on Clinical Global Impression - Global Improvement (CGI-I) at up to 6 Weeks [ Time Frame: up to 6 weeks ] [ Designated as safety issue: No ]
  • Change from Baseline in Systolic Blood Pressure at up to 6 Weeks [ Time Frame: Baseline and up to 6 weeks ] [ Designated as safety issue: Yes ]
  • Change from Baseline in Diastolic Blood Pressure at up to 6 Weeks [ Time Frame: Baseline and up to 6 weeks ] [ Designated as safety issue: Yes ]
  • Change from Baseline in Pulse Rate at up to 6 Weeks [ Time Frame: Baseline and up to 6 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 549
Study Start Date: April 2012
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lisdexamfetamine dimesylate Drug: Lisdexamfetamine dimesylate
Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
Other Name: SPD489, Vyvanse, LDX
Active Comparator: Methylphenidate Hydrochloride Drug: Methylphenidate Hydrochloride
Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
Other Name: Concerta, OROS-MPH
Placebo Comparator: Placebo Drug: Placebo
Daily oral dosing in the AM for 6 weeks


Ages Eligible for Study:   13 Years to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject must be 13-17 years of age, inclusive, at the time of consent.
  • Subject must weigh more than 79.5lb.
  • The parent/LAR must be available at approximately 7:00AM (±2 hours) to dispense the dose of investigational product for the study duration.
  • Subject, who is a female, must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test and a negative urine pregnancy test and agree to comply with any applicable contraceptive requirements of the protocol.
  • Subject has an ADHD-RS-IV total score ≥28.
  • Subject is able to swallow a capsule.
  • Subject does not have hypertension and has a resting sitting blood pressure less than or equal to 135/85mmHg.

Exclusion Criteria

  • Subject has a current, controlled (with medications prohibited in this study) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any significant comorbid Axis II disorder or significant Axis I disorder (such as post traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, depressive or anxiety disorder.
  • Diagnosis of conduct disorder. Oppositional defiant disorder is not exclusionary.
  • Subject is considered a suicide risk, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded.
  • Subject is underweight or overweight.
  • Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition. Mild, stable asthma is not exclusionary.
  • Subject has a history of seizures (other than infantile febrile seizures), a chronic or current tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
  • Subject has a known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place him/her at increased vulnerability to the sympathomimetic effects of a stimulant medication.
  • Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  • Subject has any clinically significant ECG or clinically significant laboratory abnormality.
  • Subject has current abnormal thyroid function, defined as abnormal thyroid stimulating hormone (TSH) and thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
  • Subject has a documented allergy, hypersensitivity, or intolerance to amphetamine or to any excipients in the investigational product.
  • Subject has a documented allergy, hypersensitivity, or intolerance to MPH or to any excipients in the reference product.
  • Subject has failed to fully respond to an adequate course(s) (dose and duration) of MPH or amphetamine therapy.
  • Subject has a history of suspected substance abuse or dependence disorder (excluding nicotine). Subjects with a lifetime history of amphetamine, cocaine, or other stimulant abuse and/or dependence will be excluded.
  • Subject has a positive urine drug result.
  • Subject has previously participated in this study or another clinical study involving SPD489/NRP104.
  • Subject has glaucoma.
  • Subject is required to take or anticipates the need to take medications that have CNS effects or affect performance, such as sedating antihistamines and decongestant sympathomimetics, or are monoamine oxidase inhibitors. Stable use of bronchodilator inhalers is not exclusionary.
  • Subject is female and is pregnant or lactating.
  • Subject is well controlled on his/her current ADHD medication.
  • Subject has a pre-existing severe gastrointestinal tract narrowing.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01552902

  Show 95 Study Locations
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: Shire Identifier: NCT01552902     History of Changes
Other Study ID Numbers: SPD489-406, 2011-005452-34
Study First Received: March 6, 2012
Last Updated: June 6, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Shire:

Additional relevant MeSH terms:
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Mental Disorders
Mental Disorders Diagnosed in Childhood
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on March 03, 2015